WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

β-Lactams and β-Lactamase Inhibitors: An Overview

(2016) Karen Bush et al.   Cold Spring Harbor Perspectives in Medicine

A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens

(2015) Karen Bush   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam

(2013) Michael N. Dudley et al.   CLINICAL INFECTIOUS DISEASES

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

(2013) H. W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Determining a clinical framework for use of cefepime and  -lactam/ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- -lactamase-producing Enterobacteriaceae

(2013) H. M. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cefepime: a reappraisal in an era of increasing antimicrobial resistance

(2008) Andrea Endimiani et al.   Expert Review of Anti-Infective Therapy